JP2022543771A5 - - Google Patents
Info
- Publication number
- JP2022543771A5 JP2022543771A5 JP2022506328A JP2022506328A JP2022543771A5 JP 2022543771 A5 JP2022543771 A5 JP 2022543771A5 JP 2022506328 A JP2022506328 A JP 2022506328A JP 2022506328 A JP2022506328 A JP 2022506328A JP 2022543771 A5 JP2022543771 A5 JP 2022543771A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- chain variable
- variable domain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025020903A JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880449P | 2019-07-30 | 2019-07-30 | |
| US62/880,449 | 2019-07-30 | ||
| PCT/US2020/044263 WO2021022039A1 (en) | 2019-07-30 | 2020-07-30 | Antigen-binding protein constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020903A Division JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543771A JP2022543771A (ja) | 2022-10-14 |
| JP2022543771A5 true JP2022543771A5 (enExample) | 2023-06-28 |
| JP7635201B2 JP7635201B2 (ja) | 2025-02-25 |
Family
ID=72088381
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506328A Active JP7635201B2 (ja) | 2019-07-30 | 2020-07-30 | 抗原結合タンパク質構築物及びその使用 |
| JP2025020903A Pending JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025020903A Pending JP2025072609A (ja) | 2019-07-30 | 2025-02-12 | 抗原結合タンパク質構築物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220281984A1 (enExample) |
| EP (1) | EP4003534A1 (enExample) |
| JP (2) | JP7635201B2 (enExample) |
| KR (1) | KR20220053577A (enExample) |
| CN (2) | CN114746123A (enExample) |
| AU (1) | AU2020321368B2 (enExample) |
| BR (1) | BR112022001693A2 (enExample) |
| CA (1) | CA3149199A1 (enExample) |
| IL (1) | IL290233A (enExample) |
| MX (2) | MX2022001286A (enExample) |
| WO (1) | WO2021022039A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117529499A (zh) | 2021-02-03 | 2024-02-06 | 神话治疗股份有限公司 | 抗met抗体和其用途 |
| US20260209386A1 (en) | 2022-05-19 | 2026-07-23 | Mythic Therapeutics, Inc. | Ptk7-binding proteins with ph-dependent binding and uses thereof |
| CN115329965B (zh) * | 2022-08-16 | 2025-08-01 | 北京有竹居网络技术有限公司 | 数据处理方法和电子设备 |
| CN120035607A (zh) | 2022-10-12 | 2025-05-23 | 神话治疗股份有限公司 | Lrrc-15结合蛋白构建体及其用途 |
| KR20250122502A (ko) | 2022-12-11 | 2025-08-13 | 마이틱 테라퓨틱스, 인크. | 항-cMET 항체 약물 접합체 및 이의 치료적 용도 |
| EP4688865A2 (en) | 2023-03-29 | 2026-02-11 | Mythic Therapeutics, Inc. | Trop2-binding proteins and uses thereof |
| WO2024263932A2 (en) | 2023-06-23 | 2024-12-26 | Mythic Therapeutics, Inc. | Itgb6-binding proteins and uses thereof |
| TW202602935A (zh) | 2024-04-01 | 2026-01-16 | 美商米西克治療公司 | 抗原結合蛋白構築體及其用途 |
| WO2025245128A1 (en) | 2024-05-20 | 2025-11-27 | Mythic Therapeutics, Inc. | Antibody drug conjugates and therapeutic uses thereof |
| WO2026112478A1 (en) | 2024-11-24 | 2026-05-28 | Mythic Therapeutics, Inc. | Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof |
| WO2026136884A1 (en) * | 2024-12-22 | 2026-06-25 | Conjugatebio Inc. | Bispecific antibody-drug conjugates against her3 and c-met |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201920257A (zh) * | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| NZ602220A (en) * | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| CN102174106B (zh) * | 2011-03-17 | 2013-04-10 | 朱进 | 抗Met人源Fab及其阿霉素偶联物和其制法及应用 |
| SG10201704846VA (en) * | 2012-03-14 | 2017-07-28 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| PE20181336A1 (es) * | 2015-09-18 | 2018-08-21 | Chugai Pharmaceutical Co Ltd | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos |
| RS61659B1 (sr) * | 2016-05-17 | 2021-04-29 | Abbvie Biotherapeutics Inc | Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu |
| TWI760396B (zh) * | 2016-06-17 | 2022-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
| EP3519440A4 (en) * | 2016-09-29 | 2020-03-25 | Mitsubishi Tanabe Pharma Corporation | MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF |
| US20210283249A1 (en) * | 2016-11-16 | 2021-09-16 | Eli Lilly And Company | Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
| TW201825515A (zh) * | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Ｍｅｔ抗體以及其免疫結合物及用途 |
| CN117529499A (zh) * | 2021-02-03 | 2024-02-06 | 神话治疗股份有限公司 | 抗met抗体和其用途 |
-
2020
- 2020-07-30 KR KR1020227006745A patent/KR20220053577A/ko active Pending
- 2020-07-30 WO PCT/US2020/044263 patent/WO2021022039A1/en not_active Ceased
- 2020-07-30 MX MX2022001286A patent/MX2022001286A/es unknown
- 2020-07-30 CN CN202080066488.1A patent/CN114746123A/zh active Pending
- 2020-07-30 EP EP20757450.0A patent/EP4003534A1/en active Pending
- 2020-07-30 JP JP2022506328A patent/JP7635201B2/ja active Active
- 2020-07-30 BR BR112022001693A patent/BR112022001693A2/pt unknown
- 2020-07-30 CA CA3149199A patent/CA3149199A1/en active Pending
- 2020-07-30 CN CN202510154248.1A patent/CN120285218A/zh active Pending
- 2020-07-30 US US17/630,824 patent/US20220281984A1/en active Pending
- 2020-07-30 AU AU2020321368A patent/AU2020321368B2/en active Active
-
2022
- 2022-01-28 MX MX2025011030A patent/MX2025011030A/es unknown
- 2022-01-30 IL IL290233A patent/IL290233A/en unknown
-
2025
- 2025-02-12 JP JP2025020903A patent/JP2025072609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7607498B2 (ja) | 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用 | |
| Arezumand et al. | Nanobodies as novel agents for targeting angiogenesis in solid cancers | |
| JP6670275B2 (ja) | 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体 | |
| Bell et al. | Differential tumor-targeting abilities of three single-domain antibody formats | |
| JP6817492B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| JP6917357B2 (ja) | 癌治療に使用する放射標識抗体断片 | |
| JP2022535452A5 (enExample) | ||
| JP2022534808A5 (enExample) | ||
| CN111848805B (zh) | 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体 | |
| Zhao et al. | Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model | |
| JP2022514786A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| JP2021506817A5 (enExample) | ||
| JP2025181917A5 (enExample) | ||
| JP2025510642A5 (enExample) | ||
| JP2022551844A5 (enExample) | ||
| JP2022514477A5 (enExample) | ||
| JP2021516670A (ja) | 抗ｔｒａｉｌｒ２抗体−毒素−複合体およびその抗腫瘍治療における薬物用途 | |
| WO2023222135A9 (en) | A method of treating solid tumor | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP2024535851A5 (enExample) | ||
| US20250197501A1 (en) | Recombinant antibody, immunoconjugate comprising the same, and uses thereof in treating cancers | |
| HK40120258A (en) | A method of treating solid tumor | |
| TW202321295A (zh) | 用於治療癌症的結合ｃｈｉ３ｌ１抗體、其醫藥組成物、其抗體藥物複合體、其核酸分子及其用途 | |
| JP2025520651A (ja) | 抗トランスサイレチン（ｔｔｒ）結合タンパク質及びその使用 |